MedTrace Logo

The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients

NCT03019315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2017-01-16

No results posted yet for this study

Summary

Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer. The benefit of standard chemotherapeutic regimens including taxane has not been established. This study was conducted to investigate the influences of regimens of front-line chemotherapy on on recurrence and survival for early-stage ovarian adenocarcinoma. Further, the study will analyze cost-effectiveness of different regimens

Conditions

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Wen-Fang Cheng, Ph.D. · Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019315 on ClinicalTrials.gov